Finally, to demonstrate the utility of transcriptome-based testing in improving therapy selection in AML, we identify a subset of high-risk patients with dysregulated integrin signaling, which is potentially amenable to inhibitors of focal adhesion kinase (FAK). Here, PTK2 is linked to acute myeloid leukemia.